Phase 3 N=349 Does Endometrial Injury Improve Intrauterine Insemination Outcome?
Infertility
Primary: Chemical Pregnancy Rate — 40; 19 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=872 Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
HIV · HIV Infections
Primary: Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48 — 91.6; 88.5 percentage of participants — p=0.13
Phase 3 N=1,684 The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
Coronary Artery Disease
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months — 6.4; 6.4 percentage of participants
Phase 3 N=81 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Anovulation · Oligo-ovulation · Hypothalamic-pituitary Dysfunction
Primary: Percentage of Subjects With Ovulation Mid-luteal Serum Progesterone (P4) Level of Greater Than or Equal (>=) 5 Nanogram Per Milliliter (ng/mL) or Clinical Pregnancy…
Phase 3 N=1,186 A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Diabetes Mellitus, Type 2
Primary: Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26 — -1.30; -1.37; -1.42; -1.77 percentage of hemoglobin — p=0.001
Phase 3 N=46 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
Invasive Fungal Infections · Hematologic Malignancies
Primary: Incidence of Invasive Fungal Infection (IFI) — 0; 5 percentage of participants
Phase 3 N=515 Study of Options for Second-Line Effective Combination Therapy (SELECT)
HIV-1 Infection
Primary: Cumulative Probability of Virologic Failure by Week 48 — 10.3; 12.4 cumulative probability per 100 persons
Phase 3 N=80 First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
Uveitis
Primary: Number of Participants Achieving Treatment Success — 24; 15 participants — p=0.09
Phase 3 N=44 An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes
Diabetic Autonomic Neuropathy
Primary: Global [11C]HED Retention Index (RI) — 0.081; 0.073; 0.070; 0.074 Retention index — p=0.32
Phase 3 N=1,532 Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set — -7.65…
Phase 3 N=493 Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -0.40; -0.41; -0.58 percentage of glycosylated haemoglobin
Phase 3 N=615 Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Hyperlipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — 0.10; -1.34; -17.75; -18.57 percent change — p=<0.001
Phase 3 N=3,195 Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects…
Phase 3 N=629 Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment — -0.40; -0.39 percentage of glycosylated haemoglobin
Phase 3 N=460 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.00; -1.40 percentage of glycosylated haemoglobin